BioVie Inc. (BIVI)
NASDAQ (CM) NASDAQ (CM) Primary 
BioVie Inc. (BIVI) Discusses Clinical Updates on Bezisterim and BIV201 for Parkinson's, Alzheimer's, and Ascites Transcript
BioVie Inc. (BIVI) Discusses Clinical Updates on Bezisterim and BIV201 for Parkinson's, Alzheimer's, and Ascites Transcript
BioVie: Long COVID trial fully enrolled – ICYMI
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week announced that its Phase 2 long COVID trial evaluating bezisterim has achieved full enrollment, marking an important milestone for the biotechnology company as it advances a potential treatment for patients suffering persistent post-COVID symptoms. Speaking with Proactive, CEO Cuong Do said the study enrolled more than 200 long COVID patients with support from major medical institutions including Yale, Mount Sinai, Mayo Clinic and Stanford.
BioVie completes enrollment in Phase 2 Long COVID trial
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Tuesday it has completed enrollment in its ADDRESS-LC Phase 2 clinical trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID, with topline data expected later this summer. The trial, fully funded by a grant from the US Department of War, is testing whether bezisterim can address neurological and neuropsychiatric symptoms associated with Long COVID, including fatigue, cognitive dysfunction, post-exertional malaise and sleep disturbance.
BioVie completes final patient visit in Parkinson's drug trial
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed the last patient evaluation visit in its SUNRISE-PD Phase 2 clinical trial testing drug candidate bezisterim in early-stage Parkinson's disease, with topline results expected in the third quarter. The NASDAQ-listed clinical-stage company said the completion of the final visit marks the start of the study closeout process.
BioVie Inc. (BIVI) Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology Transcript
BioVie Inc. (BIVI) Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology Transcript
BioVie CEO shares insights into long COVID trial - ICYMI
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week outlined progress in its clinical program targeting long COVID, highlighting both the scale of the unmet need and the potential for a first-in-class treatment. In an interview with Proactive, CEO Cuong Do said that approximately 17 million Americans are affected by long COVID, with symptoms ranging from brain fog and fatigue to more severe functional impairments.
BioVie abstract on Parkinson's drug accepted for neurology conference
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Tuesday an abstract from its mid-stage study of experimental Parkinson's disease treatment bezisterim has been accepted for presentation at an upcoming neurology conference. The abstract, based on the company's SUNRISE-PD trial evaluating bezisterim in patients with early Parkinson's disease, will be presented at the American Academy of Neurology Annual Meeting later this week.
BioVie CEO explains Bezisterim Parkinson's trial results - ICYMI
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week outlined its evolving approach to Parkinson's disease, with CEO Cuong Do highlighting the company's focus on neuroinflammation and insulin resistance as key drivers of the condition. Speaking to Proactive, Do explained that while Parkinson's is commonly associated with dopamine deficiency and loss of muscle control, this represents only part of the disease mechanism.
BioVie targets Parkinson's at its source with lead drug bezisterim
For decades, treatment of Parkinson's disease has centered on replacing dopamine, the neurotransmitter whose decline drives the disease's hallmark motor symptoms. But while therapies such as levodopa can temporarily restore movement, they do little to address the underlying neurodegeneration, and often introduce complications of their own.
Nasdaq, S&P 500 in the red as investors digest slower GDP and steady inflation
4:05pm: In the red US stocks remained under pressure on Friday afternoon as investors reacted to new data indicating slowing economic growth amid the...
BioVie to present Parkinson's study data at AD/PD 2026 conference
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that an abstract from its SUNRISE-PD study evaluating its lead candidate bezisterim (NE3107) for Parkinson's disease has been accepted for presentation at the AD/PD 2026 Advances in Science & Therapy annual meeting. The conference is scheduled to take place March 17 to 21, 2026, in Copenhagen, Denmark.
BioVie highlights bezisterim research at ACP meeting
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Thursday that two abstracts highlighting research on its lead drug candidate bezisterim (NE3107) have been accepted for presentation at the 2026 American College of Psychiatrists annual meeting in Bonita Springs, Florida. The abstracts, which focus on bezisterim's potential in Alzheimer's disease and Long COVID, will be presented as posters on February 18.
